{"name":"Basque Health Service","slug":"basque-health-service","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Placebo evening","genericName":"Placebo evening","slug":"placebo-evening","indication":"Other","status":"marketed"},{"name":"levo-bupicaine","genericName":"levo-bupicaine","slug":"levo-bupicaine","indication":"Other","status":"marketed"},{"name":"Placebos morning","genericName":"Placebos morning","slug":"placebos-morning","indication":"Control arm in phase 3 clinical trials","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"ASA evening","genericName":"ASA evening","slug":"asa-evening","indication":"Secondary prevention of cardiovascular events (myocardial infarction, stroke, transient ischemic attack)","status":"phase_3"},{"name":"Acetylsalicylic morning","genericName":"Acetylsalicylic morning","slug":"acetylsalicylic-morning","indication":"Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke)","status":"phase_3"}]}],"pipeline":[{"name":"ASA evening","genericName":"ASA evening","slug":"asa-evening","phase":"phase_3","mechanism":"Aspirin inhibits platelet aggregation by irreversibly acetylating cyclooxygenase (COX) enzymes, reducing thromboxane A2 production.","indications":["Secondary prevention of cardiovascular events (myocardial infarction, stroke, transient ischemic attack)","Primary prevention of cardiovascular disease in high-risk patients"],"catalyst":""},{"name":"Placebo evening","genericName":"Placebo evening","slug":"placebo-evening","phase":"marketed","mechanism":"Placebo evening is an inert substance with no active pharmacological mechanism, used as a control or comparator in clinical studies.","indications":[],"catalyst":""},{"name":"levo-bupicaine","genericName":"levo-bupicaine","slug":"levo-bupicaine","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Acetylsalicylic morning","genericName":"Acetylsalicylic morning","slug":"acetylsalicylic-morning","phase":"phase_3","mechanism":"Acetylsalicylic acid irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to provide anti-inflammatory, analgesic, and antiplatelet effects.","indications":["Cardiovascular disease prevention (secondary prevention post-myocardial infarction or stroke)","Acute coronary syndrome","Pain and fever management","Inflammatory conditions"],"catalyst":""},{"name":"Placebos morning","genericName":"Placebos morning","slug":"placebos-morning","phase":"phase_3","mechanism":"Placebos are inert substances that produce therapeutic effects through psychobiological mechanisms including expectation, conditioning, and natural disease course.","indications":["Control arm in phase 3 clinical trials"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5YVWJHTUZZWS13aWdrUGRCLVVBRk94NGhWTFBTdkhwT1hCZnlkdXEtbzVwMWVfZ0Q3Q05UTDNlMVZhMTVsa3RCSTVRTmk4UzQ4anFDeXF6elh0RC1D?oc=5","date":"2026-02-05","type":"pipeline","source":"EurekAlert!","summary":"A global challenge posed by the presence of pharmaceuticals in the environment - EurekAlert!","headline":"A global challenge posed by the presence of pharmaceuticals in the environment - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPN1E0UXotZ2RZNXI0cjh4b0xhQXNQM1ZsT0lBeEpoS3RsajZ1T1I1emFHcFZtN2tWUnVqdklETmRfQ0J6MHBRSXlwalQ5REx5c19Ed24xOXpVOS1ZNktmMDBLNzVOYTgtaFg4M2pfck5iUFkwQm5fdXlTa3FKQTExT1B6UEtlbEcyam5BZ2JlYw?oc=5","date":"2026-02-05","type":"pipeline","source":"pharmaphorum","summary":"Strategies for creating an ecosystem to support early-stage biotechs - pharmaphorum","headline":"Strategies for creating an ecosystem to support early-stage biotechs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPd0dtSElZQi1xenlXRXRxaGVLVXRLNTZzbmVscmE1SnFabFoyNWtEZjJEdk4yemFaMk1sV1BiWVk2NGdSc0d3c055bE9laXotSlZqRk5vVTNTRU1FaTdTSExkc0xzTG9pZTU5aFZfak5NMC01Y2JQWng4MTNmRTk0amVuaHFRMmRoaTVYM2NSdEFCdVhvUWczckhJQ1pkNFJ5d3lYQXZn0gGrAUFVX3lxTE5iVm9oVEEwZmxGRzhzQnlLRUJ5cktVa2wzc1hJMlUxZExobjRNZE9ndENEcmx3MjNuSkQ2bHZIcjJsUGsyWXB6blVXQUk3c2ctdnhzX3FtMzhDeW5UM3J5QmpaY0dqV0dFOVA0ZWoyZ3F0UjRIRm1EMW5PdVdiWms5WWZGdndIaEVycGV0YzRGUV8wTjdvQllEWEFpQUNmWlZCNUt5U05YNnBsSQ?oc=5","date":"2026-01-29","type":"patent","source":"Al Jazeera","summary":"Spain launches probe as expired vaccines given to 253 children - Al Jazeera","headline":"Spain launches probe as expired vaccines given to 253 children","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOUV9ibHRUcjc3NTE2a0VBZDJtNDdnWTRTUzNuNXdCcnVJYmk5dndfbFBJc0JDSFBnSXJfQi1oQzlCZHhrZTViLVlHMUtWYWZ3Q1hjZ2lidjlZcF9Lbnh0RkJ0MXRkTEl2Ry1sVzdoampVdXdudzNoNVpORlRYWFFQbEdNdw?oc=5","date":"2025-11-05","type":"pipeline","source":"CBC","summary":"With no additional pharmacare money in federal budget, some fear New Brunswick will miss out - CBC","headline":"With no additional pharmacare money in federal budget, some fear New Brunswick will miss out","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9OWnhFTmZxVHNnV2Fqdzg4SEJGSENRMFYzU3NsQk1NS0JSdXcyUUhZN0RFT1RlY1ZYaHdFMkJVVUJWQTlMX09TaDhpSG9sbzRaT0U5OXlFOXBGNzB4dHhZ?oc=5","date":"2025-08-27","type":"pipeline","source":"nature.com","summary":"Stepwise approach to alzheimer’s disease diagnosis in primary care using cognitive screening, risk factors, neuroimaging and plasma biomarkers - nature.com","headline":"Stepwise approach to alzheimer’s disease diagnosis in primary care using cognitive screening, risk factors, neuroimaging","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE55RWZtbTJoMzY5eHhNbGZKVUp2emJ0NDZKeVB5c2NtWUxxVWRQQVBIRnE0YzBweURjUTJGUmczOTd0RE9HWmNad3VjQ3laWkVjX2ZjUHZlRS1kVVJ2S1JPZGt5bkJaMVFpQkxOZ3pBVVU5OHda?oc=5","date":"2024-09-18","type":"pipeline","source":"British Pharmacological Society | Journals","summary":"Incorporating the One Health Philosophy into pharmacovigilance: Ecopharmacovigilance - British Pharmacological Society | Journals","headline":"Incorporating the One Health Philosophy into pharmacovigilance: Ecopharmacovigilance - British Pharmacological Society |","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNLVJWNVVSTUdvc2h3cWhxWDBtZVlNVGdGbHNXdVJRdW1NQ2pPZjM4QnRiMUx5TlYtckNmWTFzNk0yN1ItVE5fM3R4elMxWTVkQ2VKdGgxNmZZVHJ5b29KTEVqYlgwRzEyeVVfVm1BSm5TRkpEeVI5U3dxdkU0RS1fNXBXZkwzM2xMbzlGcE45d2FzOVY3eE5ZeVBWX2ZhMGlVREdoWHRseDQ3SkJlXzFfdWtDckpQaDV6Z0t5LVZQMXUyUHMwQzNTZy1nVzE?oc=5","date":"2024-07-29","type":"pipeline","source":"dovepress.com","summary":"IPRP - dovepress.com","headline":"IPRP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQcEpvV0wyd01uMU9pcHl3dEYxd1N5S3dQb3Q1Q29BVWcwUHNFZ3d5V2F1M0RxRFN0V3BueEVIa2RuRUVxNThvbWN3aEZQRUw2RlcwX0VVOHZEbTN3YzFhZ3p4aUV6dTE1LW1UdTZadEdWMFdTXzg5M2RnT19lT0l1Y3YxSVpGZ3Z2cnl2R1RaSlZWVy1WUUE?oc=5","date":"2024-02-11","type":"pipeline","source":"Frontiers","summary":"Descriptive and predictive analysis identify centenarians' characteristics from the Basque population - Frontiers","headline":"Descriptive and predictive analysis identify centenarians' characteristics from the Basque population","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOcDBaWHM4NE9XZ1BhWkdkdXlKVkhSaDJpWU42TjNERG1sTFJFQ0IyRUg1Tk9xLV9XR1I5eWRmSC1pRW15bV9sWUFpTTlBNFZ2eTB4S2Y3dE91X18wS0F3ZlA5Q2VUckRseTNrdWh3MTNUOHY5VnMtVUhIRng5YnB5TFUwcXpreThzZUJkclFTenFPZzhVQVlidWlR?oc=5","date":"2023-07-27","type":"pipeline","source":"Moeve Global","summary":"Ecological medicines: green solutions from the pharma industry - Moeve Global","headline":"Ecological medicines: green solutions from the pharma industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPZEIyTEp4NjRnWGlTV0pRbm55NG8xM3MyNC14Si1oSjZoemtWUkQ3QmJ1ZHJVMUpNVjNBSnowejZ6N1BnN09heGxOblBxdmRveDJlbGgzbjhfVjN0bFcxc0syVXpiclpnaTUyVWlwclJMbTRmWFRLOUN0ejFrZHgzTllCR01rLTZaNTZmVU1SMGxOMEtoUDFGSTVwZXQyeDAycnc?oc=5","date":"2023-03-22","type":"pipeline","source":"Tecnalia","summary":"Basque Country’s 3D bioprinter for the pharmaceutical industry - Tecnalia","headline":"Basque Country’s 3D bioprinter for the pharmaceutical industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBGOE1STzZOWkx0M2w3WFpDb1FPYUU5b0drRWJqb3A2SEZ6X1dNQlBZQzMzYURORThteXlHcW00dU5Ja0ZYQUxHUzNpNk1zT1hNNWhMSTc0VmFLLTdwUmJPY1lIZ1J3MTdLbk5QWFpucVpGRnZIY2lrSF92Yw?oc=5","date":"2022-04-20","type":"trial","source":"medrxiv.org","summary":"Modeling the initial phase of COVID-19 epidemic: The role of age and disease severity in the Basque Country, Spain - medrxiv.org","headline":"Modeling the initial phase of COVID-19 epidemic: The role of age and disease severity in the Basque Country, Spain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1saXgwckgyWlV3dENMY1huNzlXNDhrYTdxRHRnQlN6TjJjMFQwVlZuZENzU25vSlpWbXpxOUlxWDd4dFZrMkt4dG5rWVBJMGJzT2J3cU9zWlJxS3hSOGw4?oc=5","date":"2020-10-14","type":"pipeline","source":"nature.com","summary":"Modelling COVID 19 in the Basque Country from introduction to control measure response - nature.com","headline":"Modelling COVID 19 in the Basque Country from introduction to control measure response","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":3,"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}